Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 10/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22302357 | 0.94 | HTR4 (0.43) | HTR4KCNH2EPHX1EPHX2HRH3 | |
| SCHEMBL24865985 | 0.88 | EPHX1 (0.41) | HTR4KCNH2EPHX1EPHX2HTR3A | |
| SCHEMBL23709475 | 0.88 | HTR4 (0.46) | HTR4KCNH2EPHX1EPHX2HRH3 | |
| SCHEMBL24941968 | 0.87 | KCNH2 (0.39) | HTR4KCNH2EPHX1EPHX2HTR3A | |
| SCHEMBL22306015 | 0.87 | EPHX1 (0.48) | HTR4KCNH2EPHX1EPHX2HTR3A | |
| SCHEMBL25101407 | 0.87 | FPR3 (0.42) | HTR4EPHX1EPHX2HRH3DPP4 | |
| SCHEMBL26141945 | 0.83 | DAO (0.35) | HTR4KCNH2EPHX1EPHX2HTR3A | |
| SCHEMBL25089654 | 0.82 | EPHX1 (0.46) | HTR4KCNH2EPHX1EPHX2CACNA1I | |
| SCHEMBL22169792 | 0.80 | EPHX1 (0.52) | KCNH2EPHX1EPHX2CACNA1IDPP4 | |
| SCHEMBL9891801 | 0.80 | MAPT (0.44) | EPHX1EPHX2DPP4PREPFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | FOGHORN THERAPEUTICS INC. (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | CS, SMARCC2, SMARCC1 | HTR4 4790/4885KCNH2 1988/4885EPHX1 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.